EUVIMEDEUVIMED entdecken
Crossref

Teicoplanin alleviates androgenetic alopecia through inhibition of androgen receptor expression and enhancing dermal papilla cell proliferation

Yuqing Zhou, Qiman Lin, Shitao Wang, Jingsong Guan, Yao Wang, Jianglin Fan

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2026.178592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Yuqing Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, School of Pha…. Hauptthemen laut MEDLINE: Alopecia, Receptors, Androgen, Teicoplanin, Hair Follicle. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Science and Technology Planning Project of Guangdong Province, Guangdong Province Introduction of Innovative R&D Team, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgenetic alopecia (AGA) is a prevalent form of hair loss primarily driven by androgen receptor (AR) signaling. Currently, therapeutic options for AGA are limited. In this study, we conducted structure-based virtual screening of 3014 known compounds and identified teicoplanin, a glycopeptide antibiotic, as having potent binding affinity for the AR ligand-binding domain along with inhibition of protein expression. To investigate the potential therapeutic effects of teicoplanin on AGA, we performed both in vitro and in vivo experiments. In vitro, treatment with teicoplanin resulted in dose-dependent enhancement of human dermal papilla cell proliferation, while AR protein levels decreased. Additionally, dihydrotestosterone (DHT) induced AGA mice were treated with teicoplanin (5 mg/kg low dose and 10 mg/kg high dose) or vehicle as a control for 17 days. Results showed that subcutaneous administration of teicoplanin significantly improved hair regrowth in high dose group (average coverage: 52.3% ± 8.8% in the teicoplanin high dose group vs. 10.5% ± 3.6% in AGA group). Furthermore, hair follicles in the teicoplanin-treated group were notably larger than those in the AGA group. Immunofluorescent analysis revealed that teicoplanin treatment significantly increased Ki-67 staining, a marker of cellular proliferation, while reducing AR staining intensity. Real-time quantitative reverse transcription polymerase chain reaction and Western blotting analyses demonstrated that teicoplanin downregulated AR and its downstream target gene, transmembrane protease serine 2, by 66% and 35%, while promoting AR ubiquitination and proteasomal degradation. Concurrently, teicoplanin enhanced β-catenin expression and upregulated vascular endothelial growth factor-A mRNA. Our findings suggest that teicoplanin may serve as a promising candidate for the treatment of AGA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaReceptors, AndrogenTeicoplaninHair FollicleDermisAndrogen Receptor AntagonistsAnimalsCell ProliferationHumansMaleMiceGene Expression Regulation

Stichwörter der Autor:innen

Androgen receptorAndrogenic alopeciaHair growthTeicoplaninUbiquitination degradation

Substanzen

Receptors, AndrogenTeicoplaninAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Guangdong Province Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, Guangdong, 5290…
  • Engineering Research Center of Characteristic Traditional Chinese Medicine and Ethnomedicine, Guangxi Engineering Research Center for High-Value Utilization of Guangxi-Produced Authentic Medicinal Herbs, Guangxi Univers…

Förderung

  • Science and Technology Planning Project of Guangdong Province
  • Guangdong Province Introduction of Innovative R&D Team
  • National Key Research and Development Program of China

Zitieren

APA

Zhou, Y., Lin, Q., Wang, S., Guan, J., Wang, Y., & Fan, J. (2026). Teicoplanin alleviates androgenetic alopecia through inhibition of androgen receptor expression and enhancing dermal papilla cell proliferation. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178592

Vancouver

Zhou Y, Lin Q, Wang S, Guan J, Wang Y, Fan J. Teicoplanin alleviates androgenetic alopecia through inhibition of androgen receptor expression and enhancing dermal papilla cell proliferation. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178592

BibTeX
@article{Zhou2026,
  author = {Zhou, Yuqing and Lin, Qiman and Wang, Shitao and Guan, Jingsong and Wang, Yao and Fan, Jianglin},
  title = {Teicoplanin alleviates androgenetic alopecia through inhibition of androgen receptor expression and enhancing dermal papilla cell proliferation},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2026.178592}
}
Kostenlos starten →